India, Oct. 28 -- Genmab A/S (GMAB) reported positive results form a Phase 3 trial evaluating Petosemtamab plus Keytruda (pembrolizumab) as a first-line treatment for patients with PD-L1 positive recurrent or metastatic head and neck cancer. The combination significantly improved overall survival and tumor response compared with pembrolizumab alone.
Head and neck squamous cell carcinoma (HNSCC) is a cancer that develops in the lining of the mouth, throat and voice box. Recurrent or metastatic disease refers to cancer that has returned or spread to other parts of the body.
In the first interim analysis of the LiGeR-HN1 trial, which compared the combination with pembrolizumab alone in a randomized, open-label study, the combinaiton reduced ...